- Last Friday, FDA Law Blog wrote about yet another 180-day exclusivity letter from the FDA, this one requesting comment on the "failure to market" forfeiture provisions of the MMA.
- FDA Law Blog also posted a very nice summary of the FDA Amendments Act, which, among other changes, revises the citizen petition process.
- GSK sued the U.S. Patent & Trademark Office last Tuesday to block implementation of the PTO’s new rules restricting patent claims and continuation applications. Read more here: Patent Docs; Patently-O; Pharmalot; WSJ Health Blog.
- The Wall St. Journal had an interesting article last week on China’s generic drug industry. In case you’re not a subscriber to the Journal, you can read the WSJ Health Blog’s summary here or Pharmalot’s here.
- On October 4, the FDA announced an initiative to streamline the generic drug approval process. GPhA reacted with skepticism.
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Orange Book Blog 
Leave a comment